Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, provide insights into upcoming Lp(a)-targeted treatments and current management strategies for improved cardiovascular outcomes.
Michael D. Shapiro, DO, and Jaime Murillo, MD, discuss the implications of high Lp(a) levels in the US population, racial disparities, and tailored interventions for high-risk groups.
Michael D. Shapiro, DO, and Erin D. Michos, MD, MHS, explain the importance of the global Lp(a)HERITAGE study, emphasizing prevalence of elevated Lp(a) among different populations and the evolving approach to assessing Lp(a) levels.
Michael D. Shapiro, DO, discusses how lipoproteins, chiefly LDL (low-density lipoprotein) and LP(a) (lipoprotein a), drive atherosclerotic heart disease.